Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder
Wang K, Fenton B, Deng Y, Anthony S, Dao V, Schindler E, Lipton R, Guirguis A, Skanderson M, Seng E, Sico J. Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder. JAMA Network Open 2023, 6: e2326371. PMID: 37523183, PMCID: PMC10391301, DOI: 10.1001/jamanetworkopen.2023.26371.Peer-Reviewed Original ResearchConceptsCalcitonin gene-related peptideSARS-CoV-2 infectionSevere COVID-19 outcomesCGRP mAbsMechanical ventilationSupplemental oxygenCOVID-19 outcomesSARS-CoV-2Cohort studyCGRP antagonistMAIN OUTCOMEMigraine disordersPositive SARS-CoV-2 test resultSARS-CoV-2 test resultsCOVID-19Protocol hazard ratiosRetrospective cohort studyMonoclonal antibody treatmentGene-related peptideLikelihood of hospitalizationCourse of diseasePeptide monoclonal antibodyElectronic health recordsNeuroimmune modulatorCumulative incidence